In conclusion, this study provides convincing lines of experimental evidence that the NRF2 activation in cancer cells suppresses immune cell infiltration into tumors, which recapitulates frequently observed clinical phenotypes of the NRF2-activated malignant cancers. The gene discussed is NFE2L2; the disease is cancer.